A Phase 3 interventional study of CHF 5993 100/6/12.5 and CHF 1535 100/6 µg in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 44th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Chiesi Farmaceutici S.p.A. · Sites in Bulgaria
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
Chiesi Farmaceutici S.p.A. · Sites in Argentina, Bosnia and Herzegovina, Bulgaria and 11 more countries
Ages 18–75
Chiesi Pharma AB, Nordic · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 24 · Phase 4 4
First in 2002; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,155 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 97 across the 66 interventional studies, 300 across the 15 observational. Of the 69 that completed or were terminated, 13 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
2 of the studies in Asthma by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07301736Chiesi Farmaceutici S.p.A.Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | 2027-06-03 |
| NCT06908421Chiesi Pharma AB, NordicEfficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate [FF]), with regard to lung functions parameters and rate of exacerbations as well as safety and health economics outcomes, in adult patients with uncontrolled asthma on medium doses of inhaled corticosteroids in combination with long acting ß2 agonists (LABA).
This study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and following all other requirements of local laws.
From screening to the end of treatment, vital signs were recorded pre-dose at screening and pre- and postdose at all visits during the treatment period; physical examination was performed at all visits; concomitant medications and adverse events (AEs) were recorded, and asthma exacerbations were assessed at all visits; lung function tests were performed (pre-dose for forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) from screening to end of treatment visits, pre-dose for inspiratory capacity and vital capacity and postdose serial spirometry at all visits during the treatment period).
Patients completed the electronic diary from home twice daily from the time of screening until the end of treatment, to record asthma symptoms, treatment compliance, and use of rescue medication. Patients used the electronic peak flowmeter to record peak expiratory flow twice daily from home from the time of screening until the end of treatment.
Asthma Control Questionnaire© (ACQ)-7 was completed at screening and all visits during the treatment period. The EuroQuality of Life-5-Dimensional-3-Level questionnaire, and health economic and outcome assessments were competed at all visits during the treatment period.
Rescue medication (salbutamol 100 μg per inhalation) was permitted throughout the treatment period when absolutely needed; the maximum allowed dose was 8 inhalations/day (800 μg).
An independent Data Safety Monitoring Board was established to provide impartial safety evaluation and assurance for patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHF 5993 100/6/12.5 CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB BDP=Beclometasone Dipropionate bid=Twice daily FF=Formoterol Fumarate GB=Glycopyrronium Bromide
Drug: CHF 5993 100/6/12.5
CHF 1535 100/6 µg CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF BDP=Beclometasone Dipropionate bid=Twice daily FF=Formoterol Fumarate
Drug: CHF 1535 100/6 µg
BDP=Beclometasone Dipropionate 100µg; FF=Formoterol Fumarate 6µg; GB=Glycopyrronium Bromide 12.5µg.
BDP=Beclometasone Dipropionate 100µg; FF=Formoterol Fumarate 6µg.
1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26
Change from baseline in pre-dose FEV1 was analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) to Week 26.
2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period
Asthma exacerbation (events): Moderate AND Severe. Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
3_Change From Baseline in Peak(0-3h) FEV1 at Week 26
Peak FEV1 was analysed within 3 hours post-dose. FEV1=Peak of forced expiratory volume in the first second
Time frame: Week 0 (pre-treatment, baseline) and Week 26.
4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment
Change from baseline in the average morning PEF over the 26-Week treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 26.
5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis
Severe Asthma Exacerbation Rate over the 52-Week Treatment Period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: The entire treatment period; up to Week 52.
6_Change From Baseline in Peak FEV1 (0-3h) at All Clinical Visits
Change from baseline in peak FEV1 (within 3 h post-dosing) at all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
7_Change From Baseline in Pre-Dose FEV1 at All Clinical Visits
Results show the change from baseline in pre-dose FEV1 at all clinical visits.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
8_FEV1 Response (FEV1 ≥ 100 mL) at Week 26 and Week 52
Results show the percentage of patients classified as FEV1 responders at both Week 26 and Week 52. FEV1 response: Change from baseline in pre-dose morning FEV1 ≥ 100 mL.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
9_Change From Baseline in FEV1 Area Under the Curve (AUC) (0-3h) Normalised by Time at All Clinical Visits
Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose).
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
10_Change From Baseline in the Asthma Control Questionnaire-7 (ACQ-7) Score at All Clinical Visits
ACQ-7 Questionnaire. Asthma Control Questionnaire-7 (ACQ-7) allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
11_Asthma Control Questionnaire©-7 Response at Week 26 and Week 52
Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent the responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and Week 52.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52
12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment
Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
12b_Change From Baseline in Average Evening PEF (L/Min) Over 26 and 52 Weeks of Treatment
Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks
Data were analysed for the number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Data were analysed for the number of patients at risk of a severe asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of patients who had a severe asthma exacerbation over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (Baseline) to 52 weeks for both studies in the pooled analysis.
15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02.
Moderate asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02
Moderate and severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate and severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02
Time to first moderate or severe asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate or severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period
Moderate asthma exacerbation rate over the 52-Week treatment period.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
20_Number of Patients at Risk of a MODERATE Asthma Exacerbation
Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
21a_Change From Baseline in the Average Use of Rescue Medication Over the 26- and 52-Week Treatment Periods
Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 26 and Week 52.
21b_Change From Baseline in the Average Use of Rescue Medication in Each Inter-Visit Period
Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
22a_Change From Baseline in the Percentage of Rescue Medication-Free Days Over the 26- and 52-Week Treatment Periods
Change from baseline in the percentage of rescue medication-free days in each inter-visit period over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
22b_Change From Baseline in the Percentage of Rescue Medication-Free Days in Each Inter-Visit Period Over the Treatment
Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
23a_Change From Baseline in the Average Daily Asthma Symptom Scores Over the 26- and 52-Week Treatment Periods
Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
23b_Change From Baseline in the Average Daily Asthma Symptom Scores in Each Inter-Visit Period
Results show the change from baseline in the average daily asthma symptom scores in each inter-visit period over the entire treatment. Data was collected daily through an electronic diary from screening to the end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
24a_Change From Baseline in the Percentage of Asthma Symptom-Free Days Over the 26- and 52-Week Treatment Periods
Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
24b_Change From Baseline in the Percentage of Asthma Symptom-Free Days in Each Inter-Visit Periods
Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
25a_Change From Baseline in the Percentage of Asthma Control Days Over the 26- and 52-Week Treatment Periods
Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
25b_Change From Baseline in the Percentage of Asthma Control Days in Each Inter-Visit Period
Results show the change from baseline in the percentage of asthma control days in each inter-visit period. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
Time frame: Week 0 (pre-treatment, baseline) to Week 52.
Overall, 1628 patients were screened according to inclusion and exclusion criteria; of these,1155 patients were randomised. Overall, 5 patients were randomised in error and did not start treatment (N=3 patients in the CHF 5993 pMDI 100/6/12.5 μg group and N=2 patients in the CHF 1535 pMDI 100/6 μg group). The data set Safety population, used for the evaluations represents 1150 patients.
| Milestone | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Started | 579 | 576 |
| Completed | 542 | 539 |
| Not completed | 37 | 37 |
| Withdrew: Adverse event, serious fatal | 3 | 0 |
| Withdrew: Asthma exacerbation | 1 | 0 |
| Withdrew: Withdrawal by subject | 22 | 26 |
| Withdrew: Protocol violation | 7 | 4 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Unknown reason not specified | 2 | 0 |
Change from baseline in pre-dose FEV1 was analysed at Week 26 of treatment. FEV1=Forced expiratory volume in the first second
| Liter | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 | 0.185 (0.155 to 0.214) | 0.127 (0.098 to 0.157) |
Asthma exacerbation (events): Moderate AND Severe. Severe: asthma worsening requiring initiation of treatment with systemic corticosteroids for at least 3 days (courses of corticosteroids separated by ≥1 week treated as separate severe exacerbations). Moderate: ≥1 of the following criteria fulfilled and leading to a change in treatment (sustained increase of ≥1 puff of short acting beta 2-agonist \[SABA\] for 2 consecutive days) as shown below: * Nocturnal awakening(s) due to asthma requiring SABA for 2 consecutive nights/increase of ≥0.75 from baseline in daily symptom score on 2 consecutive days; increase from baseline in occasions of SABA use on 2 consecutive days (minimum increase 4 puffs/day); * ≥20% decrease in peak expiratory flow from baseline on at least 2 consecutive mornings/evenings or ≥20% decrease in FEV1 from baseline; * Visit to the ER/trial site for asthma treatment not requiring systemic corticosteroid.
| events/year | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period | 1.825 (1.634 to 2.037) | 2.157 (1.937 to 2.402) |
Peak FEV1 was analysed within 3 hours post-dose. FEV1=Peak of forced expiratory volume in the first second
| Liter | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 3_Change From Baseline in Peak(0-3h) FEV1 at Week 26 | 0.485 (0.453 to 0.516) | 0.401 (0.369 to 0.432) |
Change from baseline in the average morning PEF over the 26-Week treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 4_Change From Baseline in Morning Peak Expiratory Flow (PEF) Over the 26-Week Treatment | 5.325 (1.921 to 8.729) | -3.131 (-6.533 to 0.271) |
Severe Asthma Exacerbation Rate over the 52-Week Treatment Period in a pre-specified pooled analysis of 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 5_Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period - Pooled Analysis | 0.239 (0.206 to 0.276) | 0.310 (0.271 to 0.354) |
Change from baseline in peak FEV1 (within 3 h post-dosing) at all clinical visits. Baseline for pre-dose FEV1 was calculated as average of the FEV1 measurements (L) from the visit 2 (V2) Pre45min \& V2 Pre15min. If one of the two pre-dose values was missing, the baseline was equal to the available pre-dose value.
| Liter | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 0 | 0.475 (0.450 to 0.500) | 0.422 (0.397 to 0.448) |
| Week 4 | 0.520 (0.490 to 0.549) | 0.445 (0.415 to 0.474) |
| Week 12 | 0.499 (0.468 to 0.529) | 0.437 (0.406 to 0.467) |
| Week 26 | 0.485 (0.453 to 0.516) | 0.401 (0.369 to 0.432) |
| Week 40 | 0.477 (0.445 to 0.509) | 0.385 (0.353 to 0.417) |
| Week 52 | 0.472 (0.439 to 0.505) | 0.406 (0.373 to 0.439) |
Results show the change from baseline in pre-dose FEV1 at all clinical visits.
| Liter | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 4 | 0.194 (0.168 to 0.221) | 0.147 (0.120 to 0.173) |
| Week 12 | 0.195 (0.167 to 0.224) | 0.166 (0.138 to 0.195) |
| Week 26 | 0.185 (0.155 to 0.214) | 0.127 (0.098 to 0.157) |
| Week 40 | 0.188 (0.157 to 0.219) | 0.130 (0.099 to 0.161) |
| Week 52 | 0.196 (0.165 to 0.227) | 0.158 (0.127 to 0.189) |
Results show the percentage of patients classified as FEV1 responders at both Week 26 and Week 52. FEV1 response: Change from baseline in pre-dose morning FEV1 ≥ 100 mL.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 26 | 309 | 258 |
| Week 52 | 306 | 278 |
Baseline definition: mean of two pre-dose FEV1 measurements at visit 2 (V2). Results show the change from baseline in FEV1 area under the curve \[AUC\] (0-3h) at all subsequent visits (i.e. change from baseline of the AUC of the serial post-dose spirometry assessments till 3h post-dose).
| Liter | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 0 | 0.362 (0.341 to 0.384) | 0.316 (0.295 to 0.338) |
| Week 4 | 0.427 (0.399 to 0.455) | 0.351 (0.323 to 0.379) |
| Week 12 | 0.411 (0.381 to 0.440) | 0.354 (0.324 to 0.383) |
| Week 26 | 0.399 (0.368 to 0.430) | 0.314 (0.283 to 0.345) |
| Week 40 | 0.387 (0.356 to 0.418) | 0.301 (0.271 to 0.332) |
| Week 52 | 0.384 (0.352 to 0.416) | 0.324 (0.292 to 0.356) |
ACQ-7 Questionnaire. Asthma Control Questionnaire-7 (ACQ-7) allows assessment of asthma control in individual patients. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on lung function (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control (no impairment) and 6 indicating poor control (maximum impairment). The questions are equally weighted and the total score is the mean of the seven items. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. Baseline for ACQ-7 was the total score recorded at Visit 2 (Week 0) of the study. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. A negative change from baseline indicates improvement in lung function.
| score on a scale | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 4 | -0.502 (-0.551 to -0.453) | -0.453 (-0.502 to -0.403) |
| Week 12 | -0.592 (-0.646 to -0.539) | -0.576 (-0.629 to -0.522) |
| Week 26 | -0.627 (-0.681 to -0.572) | -0.584 (-0.638 to -0.529) |
| Week 40 | -0.672 (-0.729 to -0.615) | -0.627 (-0.684 to -0.571) |
| Week 52 | -0.745 (-0.801 to -0.688) | -0.722 (-0.779 to -0.665) |
Asthma Control Questionnaire (ACQ) and Asthma Control Questionnaire-7 (QAC-7) are defined in the description of Outcome measure 10 above. An ACQ-7 response was defined as change from baseline (Week 0, pre-dose) in ACQ-7 score ≤ -0.5; non-response was defined as change from baseline in ACQ-7 score \>-0.5 or missing data. Results represent the responders (i.e. change from baseline in ACQ-7 Score ≤ -0.5) at Week 26 and Week 52.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Week 26 | 317 | 291 |
| Week 52 | 350 | 340 |
Change from baseline in average MORNING PEF (L/min) over 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 12a_Change From Baseline in Average Morning PEF (L/Min) Over 52 Weeks of Treatment | 5.845 (2.009 to 9.681) | -4.406 (-8.242 to -0.571) |
Change from baseline in average EVENING PEF (L/min) over 26 and 52 weeks of treatment. PEF=Peak expiratory flow; is the volume of air forcefully expelled from the lungs in one quick exhalation.
| Liter/min | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | 5.828 (2.330 to 9.327) | -5.502 (-8.989 to -2.015) |
| Weeks 1-52 | 5.440 (1.622 to 9.259) | -7.240 (-11.048 to -3.433) |
Data were analysed for the number of patients at risk of a moderate or severe asthma exacerbation. Results show the number of patients who had moderate or severe asthma exacerbation over the 52 weeks treatment period.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 13_Number of Patients at Risk of Moderate or Severe Asthma Exacerbation Over 52 Weeks | 337 | 379 |
Data were analysed for the number of patients at risk of a severe asthma exacerbation in the pooled analysis of the two pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of patients who had a severe asthma exacerbation over the 52 weeks treatment period. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 14_Number of Patients at Risk of Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 209 | 257 |
Moderate asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-055993AB2-02 (TRIGGER). The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 15_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02. | 1.515 (1.390 to 1.651) | 1.717 (1.577 to 1.869) |
Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 16_Number of Patients at Risk of MODERATE Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 588 | 663 |
Moderate and severe asthma exacerbation rate over the 52-Week treatment period in the pooled analysis of the 2 pivotal studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate and severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| events/year | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 17_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 and CCD-055993AB2-02 | 1.788 (1.653 to 1.935) | 2.074 (1.920 to 2.241) |
Time to first moderate or severe asthma exacerbation in the Pooled Analysis of the 2 Pivotal Studies CCD-05993AB1-03 (TRIMARAN) and CCD-05993AB2-02 (TRIGGER). Results show the number of participants with moderate or severe asthma exacerbation. The pooled analysis of pivotal studies TRIMARAN and TRIGGER was a pre-specified secondary outcome measure for this study. Both studies have identical design, duration, endpoints, data collection, and statistical methodology for analyses. TRIMARAN and TRIGGER enrolled patients under medium dose and high dose ICS/LABA, respectively. Both studies were designed to assess the effect of the LAMA on ICS/LABA and showed homogeneity in terms of baseline characteristics, thus confirming the appropriateness of the pooling.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 18_Number of Patients at Risk of Moderate OR Severe Asthma Exacerbation in the Pooled Analysis of the Two Pivotal Studies CCD-05993AB1-03 and CCD-05993AB2-02 | 660 | 743 |
Moderate asthma exacerbation rate over the 52-Week treatment period.
| events/year | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 19_Moderate Asthma Exacerbation Rate Over the 52-Week Treatment Period | 1.575 (1.399 to 1.773) | 1.821 (1.621 to 2.046) |
Data were analysed for the number of patients at risk of a MODERATE asthma exacerbation.
| Participants | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| 20_Number of Patients at Risk of a MODERATE Asthma Exacerbation | 305 | 343 |
Change from baseline in the average use of rescue medication over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
| puffs/day | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | -0.475 (-0.540 to -0.410) | -0.467 (-0.532 to -0.402) |
| Weeks 1-52 | -0.533 (-0.599 to -0.467) | -0.537 (-0.603 to -0.471) |
Results show the change from baseline in the average use (puffs/day) of rescue medication in each inter-visit period. Data was collected through an electronic daily diary from screening to the end of the study.
| puffs/day | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | -0.340 ± 0.825 | -0.372 ± 0.883 |
| Visit 3 - Visit 4 Weeks 5-12 | -0.460 ± 0.998 | -0.468 ± 1.079 |
| Visit 4 - Visit 5 Weeks 13-26 | -0.494 ± 1.103 | -0.527 ± 1.141 |
| Visit 5 - Visit 6 Weeks 27-40 | -0.555 ± 1.132 | -0.616 ± 1.230 |
| Visit 6 - Visit 7 Weeks 41-52 | -0.617 ± 1.217 | -0.625 ± 1.290 |
Change from baseline in the percentage of rescue medication-free days in each inter-visit period over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study.
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | 14.702 (12.656 to 16.747) | 14.723 (12.674 to 16.772) |
| Weeks 1-52 | 16.377 (14.295 to 18.460) | 16.606 (14.519 to 18.693) |
Results show the change from baseline in the percentage of rescue medication-free days in each inter-visit period over the entire treatment. Data was collected through an electronic daily diary from screening to the end of the study.
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 9.436 ± 23.342 | 10.986 ± 25.864 |
| Visit 3 - Visit 4 Weeks 5-12 | 14.146 ± 29.065 | 15.334 ± 30.671 |
| Visit 4 - Visit 5 Weeks 13-26 | 15.620 ± 31.061 | 16.664 ± 33.840 |
| Visit 5 - Visit 6 Weeks 27-40 | 16.908 ± 31.486 | 18.948 ± 35.215 |
| Visit 6 - Visit 7 Weeks 41-52 | 18.543 ± 32.486 | 19.408 ± 36.606 |
Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Weeks of treatment. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
| score on a scale | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | -0.161 (-0.186 to -0.136) | -0.166 (-0.191 to -0.141) |
| Weeks 1-52 | -0.180 (-0.207 to -0.153) | -0.194 (-0.221 to -0.167) |
Results show the change from baseline in the average daily asthma symptom scores in each inter-visit period over the entire treatment. Data was collected daily through an electronic diary from screening to the end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered: cough, wheeze, chest tightness, breathlessness. * Morning (night-time asthma symptom score): * 0 No symptoms; * 1 Mild = Symptoms not causing awakening; * 2 Moderate = Discomfort enough to cause awakenings; * 3 Severe = Causing awakenings for most of the night/did not sleep at all. * Evening (daytime asthma symptom score): * 0 No symptoms; * 1 Mild = Aware of symptoms, which could be easily tolerated; * 2 Moderate = Discomfort enough to cause interference with daily activity; * 3 Severe = Incapacitating
| score on a scale | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | -0.102 ± 0.252 | -0.099 ± 0.275 |
| Visit 3 - Visit 4 Weeks 5-12 | -0.155 ± 0.317 | -0.161 ± 0.349 |
| Visit 4 - Visit 5 Weeks 13-26 | -0.178 ± 0.366 | -0.195 ± 0.379 |
| Visit 5 - Visit 6 Weeks 27-40 | -0.194 ± 0.397 | -0.222 ± 0.416 |
| Visit 6 - Visit 7 Weeks 41-52 | -0.210 ± 0.419 | -0.233 ± 0.435 |
Change from baseline in the percentage of asthma symptom-free days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Results show the change from baseline in the average daily asthma symptom scores over the 26- and 52-Week treatment periods. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | 14.204 (12.141 to 16.267) | 12.690 (10.623 to 14.757) |
| Weeks 1-52 | 16.847 (14.552 to 19.143) | 15.916 (13.615 to 18.217) |
Results show the change from baseline in the percentage of asthma symptom-free days in each inter-visit periods over the entire treatment. Data was collected through an electronic daily diary from screening to end of the study. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Symptoms considered by the questionnaire: cough, wheeze, chest tightness, breathlessness. An asthma symptom-free day is a day with total daily asthma symptom score = 0. For a description of the score see outcome measure number 23.
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 6.753 ± 18.224 | 5.643 ± 18.612 |
| Visit 3 - Visit 4 Weeks 5-12 | 13.511 ± 26.291 | 11.378 ± 25.671 |
| Visit 4 - Visit 5 Weeks 13-26 | 16.937 ± 29.661 | 15.575 ± 30.808 |
| Visit 5 - Visit 6 Weeks 27-40 | 18.976 ± 33.106 | 17.918 ± 33.121 |
| Visit 6 - Visit 7 Weeks 41-52 | 20.512 ± 34.124 | 19.823 ± 35.464 |
Results show the change from baseline in the percentage of asthma control days over the 26- and 52-Week treatment periods. Data was collected through an electronic daily diary from screening to the end of the study. Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Weeks 1-26 | 13.890 (11.863 to 15.916) | 12.132 (10.102 to 14.162) |
| Weeks 1-52 | 16.395 (14.154 to 18.635) | 15.109 (12.863 to 17.355) |
Results show the change from baseline in the percentage of asthma control days in each inter-visit period. A day represents data recorded in the evening session of that day plus the data recorded in the morning session of the next day. Data was collected through an electronic daily diary from screening to the end of the study Scoring of asthma symptoms (overall symptoms, cough, wheeze, chest tightness and breathlessness): Morning (night-time asthma symptoms): 0 (no symptoms), 1 (mild - symptoms not causing awakening), 2 (moderate - discomfort enough to cause awakenings) and 3 (severe - causing awakenings for most of the night/did not sleep at all). Evening (daytime asthma symptoms): 0 (no symptoms), 1 (mild: aware of symptoms that could be easily tolerated), 2 (moderate: discomfort enough to cause interference with daily activity), 3 (severe: incapacitating with inability to work/take part in usual activity).
| percentage of days | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| Visit 2 - Visit 3 Weeks 1-4 | 6.869 ± 18.066 | 5.754 ± 18.190 |
| Visit 3 - Visit 4 Weeks 5-12 | 13.212 ± 26.096 | 10.908 ± 25.058 |
| Visit 4 - Visit 5 Weeks 13-26 | 16.495 ± 29.096 | 14.794 ± 30.096 |
| Visit 5 - Visit 6 Weeks 27-40 | 18.522 ± 32.337 | 16.919 ± 32.002 |
| Visit 6 - Visit 7 Weeks 41-52 | 19.802 ± 33.330 | 18.823 ± 34.264 |
Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion at week 52 or at study discontinuation.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF 5993 100/6/12.5 µg | 3/576 (0.5%) | 28/576 (4.9%) | 429/576 (74.5%) |
| CHF 1535 100/6 µg | 0/574 (0%) | 22/574 (3.8%) | 451/574 (78.6%) |
| Event | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 7/576 | 4/574 |
| PneumoniaInfections and infestations | 0/576 | 3/574 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/576 | 2/574 |
| Atrial fibrillationCardiac disorders | 2/576 | 0/574 |
| Pancreatitis acuteGastrointestinal disorders | 2/576 | 0/574 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/576 | 1/574 |
| Mantle cell lymphoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/576 | 1/574 |
| Hypertensive crisisVascular disorders | 0/576 | 1/574 |
| Tonsillar inflammationRespiratory, thoracic and mediastinal disorders | 0/576 | 1/574 |
| Limb crushing injuryInjury, poisoning and procedural complications | 0/576 | 1/574 |
| Event | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 334/576 | 377/574 |
| NasopharyngitisInfections and infestations | 71/576 | 78/574 |
| HeadacheNervous system disorders | 38/576 | 46/574 |
| Respiratory tract infection viralInfections and infestations | 15/576 | 26/574 |
| BronchitisInfections and infestations | 18/576 | 22/574 |
| PharyngitisInfections and infestations | 12/576 | 16/574 |
| Viral upper respiratory tract infectionInfections and infestations | 12/576 | 16/574 |
| HypertensionVascular disorders | 16/576 | 9/574 |
| Back painMusculoskeletal and connective tissue disorders | 8/576 | 14/574 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/576 | 12/574 |
| Age, Categorical(Participants) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 470 | 476 | 946 |
| >=65 years | 106 | 98 | 204 |
| Age, Continuous(years) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| Mean | 52.6 ± 12.4 | 52.5 ± 12.2 | 52.5 ± 12.3 |
| Sex: Female, Male(Participants) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| Female | 355 | 353 | 708 |
| Male | 221 | 221 | 442 |
| Race (NIH/OMB)(Participants) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 575 | 574 | 1149 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Body mass index(kg/m^2) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| Mean | 27.95 ± 4.81 | 27.92 ± 5.07 | 27.94 ± 4.94 |
| Body mass index - subgroups(Participants) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| < 25 kg/m^2 | 172 | 173 | 345 |
| ≥ 25 to < 30 kg/m^2 | 231 | 231 | 462 |
| ≥ 30 kg/m^2 | 173 | 170 | 343 |
| Duration of asthma disease(years) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| Mean | 24.8 ± 12.9 | 25.2 ± 12.8 | 25.0 ± 12.8 |
| Duration of asthma disease by group(Participants) | CHF 5993 100/6/12.5 µg | CHF 1535 100/6 µg | Total |
|---|---|---|---|
| < 5 years | 32 | 29 | 61 |
| 5-20 years | 176 | 182 | 358 |
| ≥ 20 years | 368 | 363 | 731 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol, and the full Clinical Study Report (CSR), providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared patient-level data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
Access criteria: Chiesi access criteria and complete process for clinical trial data sharing is available on the Chiesi Group website.
Data sharing details ↗ · www.chiesi.com
Ran from Feb 2016 to primary completion in May 2018, 27 months.
Results were first posted in Jun 2026, 8 years 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.